Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alkermes Plc

ALKS
Current price
31.46 USD +0.27 USD (+0.87%)
Last closed 31.19 USD
ISIN USG017671052
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 4 752 154 624 USD
Yield for 12 month +21.66 %
1Y
3Y
5Y
10Y
15Y
ALKS
21.11.2021 - 28.11.2021

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, D04 C5Y6

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

34.08 USD

P/E ratio

12.8253

Dividend Yield

Current Year

+1 663 405 000 USD

Last Year

+1 111 795 000 USD

Current Quarter

+378 143 000 USD

Last Quarter

+399 131 000 USD

Current Year

+1 374 679 000 USD

Last Year

+893 687 000 USD

Current Quarter

+315 044 000 USD

Last Quarter

+336 245 000 USD

Key Figures ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 358 806 016 USD
Operating Margin TTM 27.7 %
PE Ratio 12.8253
Return On Assets TTM 8.98 %
PEG Ratio -1057.29
Return On Equity TTM 29.23 %
Wall Street Target Price 34.08 USD
Revenue TTM 1 505 121 024 USD
Book Value 7.99 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -0.7 %
Dividend Yield
Gross Profit TTM 893 687 000 USD
Earnings per share 2.29 USD
Diluted Eps TTM 2.29 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY 102.6 %
Profit Margin 22.15 %

Dividend Analytics ALKS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 2:1
Payout Ratio
Last Split Date 15.05.2000
Dividend Date

Stock Valuation ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 12.8253
Forward PE 20.3666
Enterprise Value Revenue 2.759
Price Sales TTM 3.1573
Enterprise Value EBITDA 10.4762
Price Book MRQ 3.634

Financials ALKS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALKS

For 52 weeks

22.9 USD 32.88 USD
50 Day MA 27.99 USD
Shares Short Prior Month 16 118 724
200 Day MA 26.63 USD
Short Ratio 9.09
Shares Short 16 563 164
Short Percent 15.28 %